{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:48:45Z","timestamp":1792082925311,"version":"4.4.0"},"reference-count":50,"publisher":"Impact Journals, LLC","issue":"26","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,6,27]]},"DOI":"10.18632\/oncotarget.18103","type":"journal-article","created":{"date-parts":[[2017,5,23]],"date-time":"2017-05-23T17:48:38Z","timestamp":1495561718000},"page":"41827-41840","source":"Crossref","is-referenced-by-count":21,"title":["Selective inhibition of matrix metalloproteinase-2 in the multiple myeloma-bone microenvironment"],"prefix":"10.18632","volume":"8","author":[{"given":"Gemma","family":"Shay","sequence":"first","affiliation":[{"name":"Tumor Biology Department, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilena","family":"Tauro","sequence":"additional","affiliation":[{"name":"Tumor Biology Department, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fulvio","family":"Loiodice","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Pharmaceutical Sciences, Universit\u00e0 degli Studi di Bari \u201cA. Moro\u201d, Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Tortorella","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Pharmaceutical Sciences, Universit\u00e0 degli Studi di Bari \u201cA. Moro\u201d, Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel M.","family":"Sullivan","sequence":"additional","affiliation":[{"name":"Blood and Marrow Transplantation and Cellular Immunology Department, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori A.","family":"Hazlehurst","sequence":"additional","affiliation":[{"name":"Hematopoietic Malignancy and Transplantation Program, West Virginia University, Morgantown, WV, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conor C.","family":"Lynch","sequence":"additional","affiliation":[{"name":"Tumor Biology Department, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2017,5,23]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"4673","DOI":"10.1038\/onc.2014.403","article-title":"The tumor microenvironment shapes hallmarks of mature B-cell malignancies","volume":"34","author":"Tao","year":"2015","journal-title":"Oncogene"},{"key":"2","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/S0268-960X(10)70003-5","article-title":"Multiple myeloma: biology of the disease","volume":"24","author":"Anderson","year":"2010","journal-title":"Blood reviews"},{"key":"3","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/nrclinonc.2012.15","article-title":"Latest advances and current challenges in the treatment of multiple myeloma","volume":"9","author":"Anderson","year":"2012","journal-title":"Nature reviews Clinical oncology"},{"key":"4","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1158\/1078-0432.CCR-07-2223","article-title":"The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance","volume":"14","author":"Dalton","year":"2008","journal-title":"Clin Cancer Res"},{"key":"5","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00109-015-1345-4","article-title":"Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities","volume":"94","author":"Lynch","year":"2016","journal-title":"J Mol Med (Berl)"},{"key":"6","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.bone.2010.11.008","article-title":"Biochemical and molecular mechanisms of action of bisphosphonates","volume":"49","author":"Monkkonen","year":"2011","journal-title":"Bone"},{"key":"7","first-page":"23","article-title":"TGF-beta in cancer and bone: implications for treatment of bone metastases","volume":"48","author":"Guise","year":"2010","journal-title":"Bone"},{"key":"8","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S1470-2045(11)70157-7","article-title":"Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial","volume":"12","author":"Byrne","year":"2011","journal-title":"The lancet oncology"},{"key":"9","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1016\/j.ejca.2012.08.002","article-title":"Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials","volume":"48","author":"Beuzeboc","year":"2012","journal-title":"European Journal of Cancer"},{"key":"10","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.bone.2010.06.007","article-title":"Matrix metalloproteinases as master regulators of the vicious cycle of bone metastasis","volume":"48","author":"Lynch","year":"2011","journal-title":"Bone"},{"key":"11","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/S0002-9440(10)63349-4","article-title":"Multifunctional role of matrix metalloproteinases in multiple myeloma: a study in the 5T2MM mouse model","volume":"165","author":"Vanderkerken","year":"2004","journal-title":"Am J Pathol"},{"key":"12","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1016\/j.leukres.2008.04.001","article-title":"Matrix metalloproteinases-1 and -2, and tissue inhibitor of metalloproteinase-2 production is abnormal in bone marrow stromal cells of multiple myeloma patients","volume":"32","author":"Kandefer-Szerszen","year":"2008","journal-title":"Leukemia research"},{"key":"13","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1242\/dmm.003160","article-title":"A murine model of myeloma that allows genetic manipulation of the host microenvironment","volume":"2","author":"Edwards","year":"2009","journal-title":"Dis Model Mech"},{"key":"14","first-page":"18","article-title":"The evaluation of angiogenesis and matrix metalloproteinase-2 secretion in bone marrow of multiple myeloma patients before and after the treatment","author":"Dzieciol","year":"2012","journal-title":"Advances in medical sciences"},{"key":"15","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1172\/JCI80276","article-title":"Multiple myeloma-derived MMP-13 mediates osteoclast fusogenesis and osteolytic disease","volume":"126","author":"Weiss","year":"2016","journal-title":"J Clin Invest"},{"key":"16","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1182\/blood.V90.4.1649","article-title":"Metalloproteinases in multiple myeloma: production of matrix metalloproteinase-9 (MMP-9), activation of proMMP-2, and induction of MMP-1 by myeloma cells","volume":"90","author":"Amiot","year":"1997","journal-title":"Blood"},{"key":"17","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1006\/cyto.2000.0734","article-title":"Soluble IL-6R alpha upregulated IL-6, MMP-1 and MMP-2 secretion in bone marrow stromal cells","volume":"12","author":"Amiot","year":"2000","journal-title":"Cytokine"},{"key":"18","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/path.1876","article-title":"Role of metalloproteinases MMP-9 and MT1-MMP in CXCL12-promoted myeloma cell invasion across basement membranes","volume":"208","author":"Teixido","year":"2006","journal-title":"J Pathol"},{"key":"19","doi-asserted-by":"crossref","first-page":"e29862","DOI":"10.1371\/journal.pone.0029862","article-title":"An osteoblast-derived proteinase controls tumor cell survival via TGF-beta activation in the bone microenvironment","volume":"7","author":"Lynch","year":"2012","journal-title":"PLoS One"},{"key":"20","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1126\/science.1067100","article-title":"Matrix metalloproteinase inhibitors and cancer: trials and tribulations","volume":"295","author":"Matrisian","year":"2002","journal-title":"Science"},{"key":"21","first-page":"200","article-title":"Moving targets: Emerging roles for MMPs in cancer progression and metastasis","author":"Fingleton","year":"2015","journal-title":"Matrix Biol"},{"key":"22","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2174\/138161207779313551","article-title":"Matrix metalloproteinases as valid clinical targets","volume":"13","author":"Fingleton","year":"2007","journal-title":"Curr Pharm Des"},{"key":"23","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1182\/blood.V96.12.4006","article-title":"Inhibition of matrix metalloproteinases by bisphosphonates may in part explain their effects in the treatment of multiple myeloma","volume":"96","author":"Sorsa","year":"2000","journal-title":"Blood"},{"key":"24","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1359\/jbmr.091009","article-title":"Fluorescent risedronate analogues reveal bisphosphonate uptake by bone marrow monocytes and localization around osteocytes in vivo","volume":"25","author":"Rogers","year":"2010","journal-title":"J Bone Miner Res"},{"key":"25","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1002\/jbmr.1543","article-title":"Influence of bone affinity on the skeletal distribution of fluorescently labeled bisphosphonates in vivo","volume":"27","author":"Coxon","year":"2012","journal-title":"J Bone Miner Res"},{"key":"26","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1002\/cmdc.201000540","article-title":"Biphenyl sulfonylamino methyl bisphosphonic acids as inhibitors of matrix metalloproteinases and bone resorption","volume":"6","author":"Tortorella","year":"2011","journal-title":"ChemMedChem"},{"key":"27","doi-asserted-by":"crossref","first-page":"6456","DOI":"10.1016\/j.bmc.2013.08.054","article-title":"Arylamino methylene bisphosphonate derivatives as bone seeking matrix metalloproteinase inhibitors","volume":"21","author":"Tortorella","year":"2013","journal-title":"Bioorganic & medicinal chemistry"},{"key":"28","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1158\/1535-7163.MCT-16-0315-T","article-title":"Bone-Seeking Matrix Metalloproteinase-2 Inhibitors Prevent Bone Metastatic Breast Cancer Growth","volume":"16","author":"Lynch","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"29","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1016\/j.bmcl.2014.04.077","article-title":"Dual carbonic anhydrase\/matrix metalloproteinase inhibitors incorporating bisphosphonic acid moieties targeting bone tumors","volume":"24","author":"Tortorella","year":"2014","journal-title":"Bioorganic & medicinal chemistry letters"},{"key":"30","first-page":"1634","article-title":"Phosphonate Emerging Zinc Binding Group in Matrix Metalloproteinase Inhibitors","volume":"16","author":"Tortorella","year":"2014","journal-title":"Current Drug Targets"},{"key":"31","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.3324\/haematol.2013.087809","article-title":"Transcriptome analysis reveals molecular profiles associated with evolving steps of monoclonal gammopathies","volume":"99","author":"Hernandez-Rivas","year":"2014","journal-title":"Haematologica"},{"key":"32","doi-asserted-by":"publisher","first-page":"8284","DOI":"10.18632\/oncotarget.2058","article-title":"Transcriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma cells: implications in myeloma progression and myeloma bone disease","volume":"5","author":"Garayoa","year":"2014","journal-title":"Oncotarget"},{"key":"33","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1016\/j.bmcl.2014.03.001","article-title":"Arylamino bisphosphonates: potent and selective inhibitors of the tumor-associated carbonic anhydrase XII","volume":"24","author":"Tortorella","year":"2014","journal-title":"Bioorganic & medicinal chemistry letters"},{"key":"34","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/nrc884","article-title":"Strategies for MMP inhibition in cancer: innovations for the post-trial era","volume":"2","author":"Lopez-Otin","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"35","first-page":"494","article-title":"Bone seeking matrix metalloproteinase-2 inhibitors prevent bone metastatic breast cancer growth","volume":"16","author":"Lynch","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"36","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1002\/cncr.11133","article-title":"Receptor activator of NF-kappaB ligand, macrophage inflammatory protein-1alpha, and the proteasome: novel therapeutic targets in myeloma","volume":"97","author":"Mundy","year":"2003","journal-title":"Cancer"},{"key":"37","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s10555-014-9494-4","article-title":"Integrating new discoveries into the \u201cvicious cycle\u201d paradigm of prostate to bone metastases","volume":"33","author":"Lynch","year":"2014","journal-title":"Cancer Metastasis Rev"},{"key":"38","doi-asserted-by":"crossref","first-page":"e0119546","DOI":"10.1371\/journal.pone.0119546","article-title":"NOD\/SCID-GAMMA mice are an ideal strain to assess the efficacy of therapeutic agents used in the treatment of myeloma bone disease","volume":"10","author":"Chantry","year":"2015","journal-title":"PLoS One"},{"key":"39","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1021\/pr400881p","article-title":"Extracellular matrix remodeling by bone marrow fibroblast-like cells correlates with disease progression in multiple myeloma","volume":"13","author":"Drach","year":"2014","journal-title":"Journal of proteome research"},{"key":"40","doi-asserted-by":"crossref","first-page":"21491","DOI":"10.1074\/jbc.274.31.21491","article-title":"Matrix metalloproteinases","volume":"274","author":"Woessner","year":"1999","journal-title":"Journal Biological Chemistry"},{"key":"41","doi-asserted-by":"crossref","first-page":"4683","DOI":"10.1200\/JCO.2004.08.054","article-title":"Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196","volume":"22","author":"Davidson","year":"2004","journal-title":"J Clin Oncol"},{"key":"42","doi-asserted-by":"crossref","first-page":"R109","DOI":"10.1186\/ar2315","article-title":"Development of musculoskeletal toxicity without clear benefit after administration of PG-116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis: a randomized, 12-month, double-blind, placebo-controlled study","volume":"9","author":"Spector","year":"2007","journal-title":"Arthritis research & therapy"},{"key":"43","doi-asserted-by":"crossref","first-page":"32628","DOI":"10.1074\/jbc.M806266200","article-title":"Heparanase stimulation of protease expression implicates it as a master regulator of the aggressive tumor phenotype in myeloma","volume":"283","author":"Sanderson","year":"2008","journal-title":"J Biol Chem"},{"key":"44","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1046\/j.1365-2141.1999.01180.x","article-title":"Syndecan-1 expression suppresses the level of myeloma matrix metalloproteinase-9","volume":"104","author":"Kelly","year":"1999","journal-title":"Br J Haematol"},{"key":"45","doi-asserted-by":"crossref","first-page":"694","DOI":"10.6004\/jnccn.2015.0206","article-title":"Multiple myeloma: new uses for available agents, excitement for the future","volume":"13","author":"Anderson","year":"2015","journal-title":"J Natl Compr Canc Netw"},{"key":"46","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.bbrc.2014.08.102","article-title":"Bortezomib prevents the expression of MMP-13 and the degradation of collagen type 2 in human chondrocytes","volume":"452","author":"Chen","year":"2014","journal-title":"Biochem Biophys Res Commun"},{"key":"47","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1182\/blood-2004-01-0236","article-title":"Anti-alpha4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis","volume":"104","author":"Yoneda","year":"2004","journal-title":"Blood"},{"key":"48","doi-asserted-by":"crossref","first-page":"29384","DOI":"10.1038\/srep29384","article-title":"Predictive computational modeling to define effective treatment strategies for bone metastatic prostate cancer","volume":"6","author":"Lynch","year":"2016","journal-title":"Scientific reports"},{"key":"49","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1359\/jbmr.2003.18.3.482","article-title":"Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival","volume":"18","author":"Vanderkerken","year":"2003","journal-title":"J Bone Miner Res"},{"key":"50","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1002\/cncr.21530","article-title":"Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice","volume":"104","author":"Redini","year":"2005","journal-title":"Cancer"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.18103","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T16:58:46Z","timestamp":1594832326000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.18103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,23]]},"references-count":50,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2017,6,27]]}},"alternative-id":["18103","28611279"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.18103","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,23]]}}}